Rachel Lutz

Results from a small study show that adding donepezil may provide additional analgesic relief for neuropathic pain patients who do not receive sufficient pain relief from gabapentin.

Researchers confirm that multiple sclerosis (MS) patients do experience a decrease in life expectancy when compared to their non-MS counterparts in the United States.

Patients with hepatitis C Virus who had not previously had treatment or responded to treatment displayed sustained virologic response in phase 2b of a new study.

A Federal Drug Administration advisory panel of experts has recommended that Merck's antiplatelet drug vorapaxar be approved for use as add-on therapy in patients with a history of heart attack.

Although testosterone supplementation has increased among older men in the past decade, study results show that many of these patients may not meet clinical guidelines for treatment.

Researchers from the Yale University schools of public health and medicine concluded the hepatitis C virus can remain infectious for up to six weeks on surfaces, based on their study results.

The European Association for the Study of the Liver published their updated Clinical Practice Guidelines for the management of the hepatitis C virus, which includes updates regarding people who inject recreational drugs.

A study published in The Journal of Clinical Psychiatry concludes that adults dependent on cocaine and/or methamphetamine who undergo stimulant addiction treatment does not detract from simultaneous smoking cessation therapy, and can even increase likelihood of quitting.

Results from an eight-year study in Taiwan demonstrated that antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients.

Results from animal models of depression and a human clinical trial show that enhancing, instead of blocking, the NMDA glutamate receptor can cause antidepressant-like effects.

Within a year of their diagnosis, nearly half of all first-line drug-treated MDD patients were also treated with a second-line therapy, a new study finds. Cymbalta leads the market in second-line therapy, used individually or as a combination, and Abilify is the leading atypical antipsychotic.

Researchers using mice models have shown that the compound SR2211, which targets a nuclear receptor that is a key regulator of TH17 cells, significantly reduces joint inflammation and erosion.